Penpulimab is approved for multiple indications in China, but this marks the first US approval for the novel monoclonal ...

By Michael Erman (Reuters) -Bristol Myers Squibb reported better-than-expected first-quarter revenue on Thursday and raised ...

Akeso Inc. scored U.S. FDA approval of the PD-1 monoclonal antibody penpulimab in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or ...

Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...

A quick spray of medication might seem like an easy way to get thicker hair, but some people say one sold online has left ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Cancer drugs that received accelerated approval from the FDA gained regular approval significantly faster if their ...

The FDA's move stops short of the outright ban that had been floated for in Kennedy's "Make America Healthy Again" platform ...

The frequency of high blood glucose among patients receiving PI3K/Akt inhibitors to treat breast cancer has some oncologists ...

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped ...

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data ...

The US Food and Drug Administration on Wednesday approved a cancer drug developed by China-based Akeso Inc, marking a ...